Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nightly eye drops may keep Kids' vision sharp longer

NCT ID NCT07567040

Prevention Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 7 times

Summary

This study tests whether a nightly drop of low-dose atropine in both eyes can delay the start of nearsightedness in children aged 6–11 who are not yet nearsighted. Over 600 kids will be randomly assigned to get either the atropine drops or placebo drops for two years. The main goal is to see if fewer children become nearsighted in the atropine group compared to the placebo group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atropine sulfate 0.05% eye drops
What this could lead to
If successful, this could give children a simple way to delay or prevent nearsightedness, reducing the need for glasses or contacts later.
What could go wrong
This is a Phase 3 trial, but results may not apply to all children. Atropine drops can cause light sensitivity or blurry near vision, and the effect may wear off after stopping.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 664 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 11 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano * Neither eye has -0.75 D or more myopia, spherical component * Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent * Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction * Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater) Exclusion Criteria: * If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit. * Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near * Known allergy to atropine * Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.) * Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.) * Ocular surgery (e.g., cataracts, strabismus) * Any previous myopia prevention/control therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month * Pregnancy by self-report

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Case Western Reserve Department of Ophthalmology

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44106, United States

  • Illinois College of Optometry

    RECRUITING

    Chicago, Illinois, 60616, United States

    Contact Email: •••••@•••••

  • Indiana University

    RECRUITING

    Bloomington, Indiana, 47405, United States

  • New England College of Optometry

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Email: •••••@•••••

  • Pennsylvania College of Optometry at Drexel University

    NOT_YET_RECRUITING

    Elkins Park, Pennsylvania, 19027, United States

  • Southern California College of Optometry at Marshall B. Ketchum University

    RECRUITING

    Fullerton, California, 92831, United States

    Contact Email: •••••@•••••

  • Southern College of Optometry

    RECRUITING

    Memphis, Tennessee, 38104, United States

  • Stanford University

    NOT_YET_RECRUITING

    Palo Alto, California, 94303, United States

  • State University of New York College of Optometry

    RECRUITING

    New York, New York, 10036, United States

    Contact Email: •••••@•••••

  • The Ohio State University College of Optometry

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Alabama School of Optometry

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of California, Berkeley, School of Optometry

    RECRUITING

    Berkeley, California, 94720, United States

  • University of Houston College of Optometry

    RECRUITING

    Houston, Texas, 77004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.